Business Context and Reporting Period
This Form 8-K is a current report filed by AgeX Therapeutics, Inc. (trading symbol: AGE) on October 18, 2019. The registrant is incorporated in Delaware and operates as an emerging growth company. The report addresses corporate governance matters regarding the upcoming 2019 Annual Meeting of Stockholders.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on procedural announcements regarding stockholder meetings and does not contain financial performance data.
Material Changes
There are no material financial changes reported in this filing. The primary event is the Board of Directors' decision to set the date for the 2019 Annual Meeting of Stockholders.
Guidance, Outlook, and Corporate Actions
- Annual Meeting Date: The Board of Directors has set December 30, 2019, as the date for the 2019 Annual Meeting of Stockholders.
- Proposal Deadline: Stockholders must notify the company of proposals for approval by October 31, 2019.
- Nomination Deadline: Nominating stockholders or groups must submit their notice on Schedule 14N for the inclusion of nominees in proxy materials by October 31, 2019.
- Forward-Looking Statements: The filing includes standard disclaimers regarding forward-looking statements, noting that actual results may differ materially from anticipated results due to risk factors detailed in the company's Form 10-K and 10-Q filings.
Key Facts for Investor Verification
- Verify the specific date of the 2019 Annual Meeting (December 30, 2019) against the company's official proxy statement.
- Confirm the October 31, 2019 deadline for submitting stockholder proposals and director nominations.
- Note that the company is classified as an emerging growth company, which may impact financial reporting requirements.
- Review the company's most recent Form 10-K or 10-Q for financial data, as this 8-K contains no financial metrics.